It’s no secret that Barbara Borden—the 13th most active dealmaker of all time for publicly disclosed deals, according to Deal Point Data—has led some of the largest life sciences and health care deals in the past decade. But a groundbreaking exit for legacy client Horizon Therapeutics last year just might take the cake, according to the Cooley partner.

“It was a career deal for me,” Borden said. “Horizon was such an important client to me personally … it’s bittersweet. I’ll miss them, but I’m happy for the great outcome.”